CRBP earnings call for the period ending March 31, 2020.
News & Analysis: Corbus Pharmaceuticals Holdings
These cannabinoid-based drug developers offer different risk/reward profiles.
Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.
CRBP earnings call for the period ending December 31, 2019.
If Corbus announces positive results this summer from two late-stage clinical trials, the current stock price could be a steal. But it's not for the faint of heart.
Both of these biotechs could become smash hits, but which is better?
It’s full steam ahead with a slate of late-stage clinical trial results expected in 2020. However, Corbus just released its third-quarter results, and the financial picture looks bleak.
It’s a medical marijuana showdown.
CRBP earnings call for the period ending June 30, 2019.
A licensing agreement enabled the clinical-stage biotech to report a big jump in revenue and a nice profit in Q2.